Objective To study the medication usage in patients with severe acute respiratory syndrome (SARS).
Methods The information of the medications of 680 patients with SARS in Xiao Tang Shan Hospital was collected by HIS system and classified by using computer model on the basis of disease factor. The usage time and cases, and cost of these medications were calculated. The defined daily dose (DDD) and drug utilization index (DUI) were analyzed.
Results A number of 359 drugs in 17 categories were applied to 680 patients with SARS. Most cases used antibacterial agents, the DDDs of immunomodulator and vitamins were the highest, the usage duration of vitamins and infusion fluids were the longest among 17 kinds of the drugs. The cost of methylpredni-solone injection was the highest. The mortality rate, kinds of drugs and frequency of drugs were higher in type C, type D and serious SARS patients than that of type A and common SARS patients.
Conclusions Many kinds of medications have been prescribed to SARS patients. The dosages of these medication are very high, especially glucocorticoids, immuneomodulator and nutrient agents. The computer model on the basis of disease factor is probably valid, rapid and easy to standardize.
Citation：
WANG Rui,ZHOU Xiaoqing,DONG Jun,WEI Rong,CAO Xiutang,Z HOU Yachun,WANG Jin,GUO Daihong,CHEN Kun,ZHOU Jian,WANG Jiesong,ZHU Xiumei,LIANG Beibei,XU Yanping,ZHOU Xianzhi,LI Youping,SUN Xin,XIONG Ying. Utilization Analysis of Drug Efficacy of the 680 Cases of SARS Patients in Xiao Tang Shan Hospital of PLA. Chinese Journal of Evidence-Based Medicine, 2004, 04(7): 474-481. doi:
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
［1］World Health Organization.Acute Respiratory Syndrome in Hong Kong Special Administrative Region of China/Vietnam.March 12 2003.Availabe from:URL:http://www.who.int/csr/2003.03.12/en/.
|
| 2. |
［2］Dong J,Cao XT,Liu ZM,Xu HM,Li YP,Sun X,Wang L,Zhou YC.Computerized classification study on 680 clinical confirmed SARS patients in Xiao Tang Shan Hospital [J].Chinese Journal of Evidence-Based Medicine,2004; 4(5):325-332.
|
| 3. |
董军,曹秀堂,刘志敏,许红民,李幼平,孙鑫,王莉,周亚春.小汤山医院680例SARS临床确诊病例的计算机分型研究 [J].中国循证医学杂志,2004; 4(5):325～332.
|
| 4. |
［3］Diagnosis standard of SARS.2003传染性非典型肺炎诊断标准(试行).2003.
|
| 5. |
［4］Zou H,Shao YF,Zhu CJ,Deng YL,Ma YJ,Chen SX.Principle and utilization of DDDs analyze in hospital [J].China Dispensary,1996; 7(5):215-217.
|
| 6. |
邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用 [J].中国药房,1996; 7 (5):215～217.
|
| 7. |
［5］ATC/DDD Index 2003.Availabe from:URL:http://www.whocc.no/atcddd/indexdatabase/.
|
| 8. |
［6］Chen XQ.New pharmacology [M].15th ed.Beijing,People’s Publishing House,2003.P.564company.
|
| 9. |
陈新谦主编.新编药物学 [M].第15版.北京:人民卫生出版社,2003.p.564.
|
| 10. |
［7］Interpretation of ADRs supervise software edited by WHO WHO.
|
| 11. |
国际药品不良反应监察计算机软件说明.
|
| 12. |
［8］Meng QH.antiviral treatment recommendation of SARS [C].Academic meeting of SARS,20-22.
|
| 13. |
孟庆华.传染性非典型肺炎的抗病毒治疗建议 [C].SARS诊治学术论坛,20～22.
|
| 14. |
［9］Koren G,King S,Knowles S,Phillips E.Ribavirin in the treatment of SARS:a new trick for an old drug [J] CMAJ,2003; 168:1 289-1 292.
|
| 15. |
［10］Holme KV.SARS-associated coronavirus [J].N Engl J Med,2003; 348:1 948-1 951.
|
| 16. |
［11］Zhao Z,Zhang F,Xu M,Huang K,Zhong W,Cai W,Yin Z,Huang S,Deng Z,Wei M,Xiong J,Hawkey PM.Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou,PR China [J].J Med Microbiol,2003; 52(8):715-720.
|
- 1. ［1］World Health Organization.Acute Respiratory Syndrome in Hong Kong Special Administrative Region of China/Vietnam.March 12 2003.Availabe from:URL:http://www.who.int/csr/2003.03.12/en/.
- 2. ［2］Dong J,Cao XT,Liu ZM,Xu HM,Li YP,Sun X,Wang L,Zhou YC.Computerized classification study on 680 clinical confirmed SARS patients in Xiao Tang Shan Hospital [J].Chinese Journal of Evidence-Based Medicine,2004; 4(5):325-332.
- 3. 董军,曹秀堂,刘志敏,许红民,李幼平,孙鑫,王莉,周亚春.小汤山医院680例SARS临床确诊病例的计算机分型研究 [J].中国循证医学杂志,2004; 4(5):325～332.
- 4. ［3］Diagnosis standard of SARS.2003传染性非典型肺炎诊断标准(试行).2003.
- 5. ［4］Zou H,Shao YF,Zhu CJ,Deng YL,Ma YJ,Chen SX.Principle and utilization of DDDs analyze in hospital [J].China Dispensary,1996; 7(5):215-217.
- 6. 邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用 [J].中国药房,1996; 7 (5):215～217.
- 7. ［5］ATC/DDD Index 2003.Availabe from:URL:http://www.whocc.no/atcddd/indexdatabase/.
- 8. ［6］Chen XQ.New pharmacology [M].15th ed.Beijing,People’s Publishing House,2003.P.564company.
- 9. 陈新谦主编.新编药物学 [M].第15版.北京:人民卫生出版社,2003.p.564.
- 10. ［7］Interpretation of ADRs supervise software edited by WHO WHO.
- 11. 国际药品不良反应监察计算机软件说明.
- 12. ［8］Meng QH.antiviral treatment recommendation of SARS [C].Academic meeting of SARS,20-22.
- 13. 孟庆华.传染性非典型肺炎的抗病毒治疗建议 [C].SARS诊治学术论坛,20～22.
- 14. ［9］Koren G,King S,Knowles S,Phillips E.Ribavirin in the treatment of SARS:a new trick for an old drug [J] CMAJ,2003; 168:1 289-1 292.
- 15. ［10］Holme KV.SARS-associated coronavirus [J].N Engl J Med,2003; 348:1 948-1 951.
- 16. ［11］Zhao Z,Zhang F,Xu M,Huang K,Zhong W,Cai W,Yin Z,Huang S,Deng Z,Wei M,Xiong J,Hawkey PM.Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou,PR China [J].J Med Microbiol,2003; 52(8):715-720.
